Clinical Trials ProgressFive BHV-7000 (Kv7 activator) Ph2/3 trials are underway in epilepsy, major depressive disorder (MDD) and bipolar disorder.
Drug DevelopmentBHVN is on track to report taldefgrobep alfa (myostatin inhibitor) Ph3 data in SMA and initiate a Ph2 obesity trial.
Pipeline PotentialThe current market cap of approximately $3.6 billion is baking in total pipeline contribution of around $1 billion, but the pipeline could approach $3 to 4 billion over time.